
COVID-19: Moderna reports promising interim results
On Monday, Moderna Inc. announced that two 100µg shots of its mRNA COVID-19 vaccine candidate mRNA-1273 showed an efficacy of 94,5%, according to an...

ADC company Araris Biotech raises CHF15.2m
Besides Pureos Bioventures, London-based 4BIO Capital, btov Partners, Redalpine, VI Partners and Schroder Adveq cofinanced the CHF12.7m addition to...

3P Bio to manufacture SpyBiotech vaccine
Under the agreement, Navarra-based CDMO 3P Biopharmaceuticals will produce cGMP lots for Phase I testing of SpyBiotech’s (Oxford) vaccine candidate...

How stress brings cancer to life again
An international research team led by AstraZeneca’s oncology expert Dmitry I. Gabrilovich report that that stressed neutrophils might act as a...

Roche licences antiviral nucleoside from Atea
Under the agreement, Roche will pay US$350m in cash for ex US-distribution of Atea Pharmaceuticals antiviral Phase II candidate. Atea has the option...

Drug set to rescue COVID-19 patients at ICUs
Initial data from an US expanded access (EA) use of RLF-100™ (aviptadil) in 90 ICU patients with critical COVID-19 and severe comorbidities...

Pfizer/BioNTech sign vaccine contract with EC
The deal includes an option for the European Commission to request an additional 100 million doses of BNT-162-b2. That's the largest initial order of...